SAE Media Group is proud to announce the release of the official brochure for AI in Drug Discovery 2026, taking place 9–10 March 2026 in London. The newly published agenda highlights how artificial intelligence is transforming pharmaceutical R&D, from early stage pilots to scaled, portfolio wide adoption.
The event arrives at a pivotal moment for the industry. The global market for AI in drug discovery, valued at $1.72 billion in 2024, is projected to soar to $8.53 billion by 2030, underscoring the sector’s rapid evolution and commercial momentum.
AI in Drug Discovery 2026 will showcase real world case studies, new clinical data, and next generation platforms delivering measurable gains in speed, cost efficiency, and hit quality across global research teams.
Key themes include:
- Foundation models for target identification and disease understanding
- LLMs in computational chemistry and molecular design
- Advanced cell models and simulations enabling animal reduction in preclinical research
- Practical strategies for scaling AI systems across global R&D portfolios
- Addressing barriers to full AI integration including data quality, interoperability, regulatory alignment, and ethical, explainable outputs
- Market outlook and investment trends as AI drug discovery accelerates toward $8.5B by 2030
“This year’s brochure captures a pivotal moment for AI in pharma,” said Katie Ogden, Portfolio Manager at SAE Media Group. “We are seeing a shift from experimentation to execution, where AI is no longer a future promise but a present-day driver of competitive advantage.”
Peter Clark, Conference Chair and VP, Computational Drug Design at Novo Nordisk said “Unlocking the full potential of AI in drug discovery requires more than technical progress it demands advances in data generation, quality, and automation. This year’s programme reflects that shift, spotlighting the critical enablers that will shape the future of pharmaceutical R&D.”
The programme illustrates a maturing field, with AI now embedded across molecule design, clinical trial optimisation, and preclinical modelling. Attendees will explore how generative AI, multimodal data fusion, and autonomous lab systems are reshaping the drug development pipeline.
Early bird registration is now open. Delegates who book before 7 November 2025 will save £400 on their pass.
View the brochure and secure your place – https://www.smgconferences.com/pharmaceuticals/uk/conference/drug-discovery
